For pharma stocks, it feels like depressed valuations are the new normal. Bristol-Myers Squibb (NYSE: BMY ) is a case in point - its forward price-to-earnings multiple has only turned further south since my Q3 2024 analysis. I was upbeat on shares backFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passi ...